Plain-English translation of NCT05356741 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage study testing a new medication called designed to treat cancers that have a protein called HER2 on their surface. Researchers will give the medication to patients either by itself or combined with , an immunotherapy drug already used in cancer care. The study will carefully watch how safe this treatment is and how the body processes it.
Many patients with HER2-positive cancers need better treatment options, especially when their cancer has spread or cannot be surgically removed. This medication targets HER2-positive cancers in a new way, and researchers want to see if combining it with immunotherapy might help more patients.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication at a medical center, either the new medication alone or combined with an existing immunotherapy drug, depending on which part of the study you join. The study takes place over approximately 6 years total, though individual participants may be involved for shorter periods. You will have regular clinic visits, blood tests, and imaging scans to monitor how you are responding and to watch for any side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Australia
France
Portugal